Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | PTPRB | P23467 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20422635 | 0.88 | ESR1 (0.49) | ADORA1RENAAK1MMP13ITGA4 | |
| SCHEMBL20422634 | 0.88 | ESR1 (0.49) | ADORA1RENAAK1MMP13ITGA4 | |
| SCHEMBL15702033 | 0.88 | ITGA4 (0.38) | ADORA1ITGA4ITGB7ESR1ESR2 | |
| SCHEMBL3638571 | 0.87 | LDHA (0.46) | ADORA1RENMMP13ITGA4ITGB7 | |
| SCHEMBL8362444 | 0.87 | ADORA1 (0.51) | ADORA1RENAAK1MMP13ITGA4 | |
| SCHEMBL23279486 | 0.87 | MEN1 (0.41) | ADORA1RENAAK1MMP13ITGA4 | |
| SCHEMBL18256513 | 0.87 | MEN1 (0.41) | ADORA1RENAAK1MMP13ITGA4 | |
| SCHEMBL7906205 | 0.87 | ADORA1 (0.44) | ADORA1RENAAK1MMP13ITGA4 | |
| SCHEMBL8362441 | 0.87 | ADORA1 (0.51) | ADORA1RENAAK1MMP13ITGA4 | |
| SCHEMBL1325201 | 0.87 | MMP13 (0.39) | ADORA1RENAAK1MMP13ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492345-B2 | Cyclic peptide antitumor agents | NORTHWESTERN UNIVERSITY (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120122799-A1 | CYCLIC PEPTIDE ANTITUMOR AGENTS | NORTHWESTERN UNIVERSITY (US) | 2012-05-17 | — | — | US | disclosed |
| US-8058244-B2 | Cyclic peptide antitumor agents | NORTHWESTERN UNIVERSITY (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058244-B2 | Cyclic peptide antitumor agents | NORTHWESTERN UNIVERSITY (US) | 2011-11-15 | — | — | US | disclosed |
| US-20100204088-A1 | Cyclic Peptide Antitumor Agents | SILVERMAN RICHARD B | 2010-08-12 | — | — | US | disclosed |
| US-20100204088-A1 | Cyclic Peptide Antitumor Agents | SILVERMAN RICHARD B | 2010-08-12 | — | — | US | disclosed |
| US-7709443-B2 | For treatment of human melanoma, pancreatic, breast, prostate cancer cells | NORTHWESTERN UNIVERSITY (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709443-B2 | For treatment of human melanoma, pancreatic, breast, prostate cancer cells | NORTHWESTERN UNIVERSITY (US) | 2010-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204088-A1 | Cyclic Peptide Antitumor Agents | VIP, IAPP, NGLY1 | ADORA1 4669/4885REN 4100/4885AAK1 3219/4885 |
| US-20120122799-A1 | CYCLIC PEPTIDE ANTITUMOR AGENTS | VIP, IAPP, NGLY1 | ADORA1 4669/4885REN 4100/4885AAK1 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.